Tags

Type your tag names separated by a space and hit enter

Determinants of hepatitis A vaccine immunity in a cohort of human immunodeficiency virus-infected children living in Switzerland.
Clin Vaccine Immunol. 2012 Nov; 19(11):1751-7.CV

Abstract

Vaccination in HIV-infected children is often less effective than in healthy children. The goal of this study was to assess vaccine responses to hepatitis A virus (HAV) in HIV-infected children. Children of the Swiss Mother and Child HIV Cohort Study (MoCHiV) were enrolled prospectively. Recommendations for initial, catch-up, and additional HAV immunizations were based upon baseline antibody concentrations and vaccine history. HAV IgG was assessed by enzyme-linked immunosorbent assay (ELISA) with a protective cutoff value defined as ≥10 mIU/ml. Eighty-seven patients were included (median age, 11 years; range, 3.4 to 21.2 years). Forty-two patients were seropositive (48.3%) for HAV. Among 45 (51.7%) seronegative patients, 36 had not received any HAV vaccine dose and were considered naïve. Vaccine responses were assessed after the first dose in 29/35 naïve patients and after the second dose in 33/39 children (25 initially naïve patients, 4 seronegative patients, and 4 seropositive patients that had already received 1 dose of vaccine). Seroconversion was 86% after 1 dose and 97% after 2 doses, with a geometric mean concentration of 962 mIU/ml after the second dose. A baseline CD4(+) T cell count below 750 cells/μl significantly reduced the post-2nd-dose response (P = 0.005). Despite a high rate of seroconversion, patients with CD4(+) T cell counts of <750/μl had lower anti-HAV antibody concentrations. This may translate into a shorter protection time. Hence, monitoring humoral immunity may be necessary to provide supplementary doses as needed.

Authors+Show Affiliations

Department of Pediatrics, Geneva Medical School and University Hospitals of Geneva, Geneva, Switzerland. Claire-Anne.Siegrist@unige.chNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22933400

Citation

Crisinel, Pierre Alex, et al. "Determinants of Hepatitis a Vaccine Immunity in a Cohort of Human Immunodeficiency Virus-infected Children Living in Switzerland." Clinical and Vaccine Immunology : CVI, vol. 19, no. 11, 2012, pp. 1751-7.
Crisinel PA, Posfay-Barbe KM, Aebi C, et al. Determinants of hepatitis A vaccine immunity in a cohort of human immunodeficiency virus-infected children living in Switzerland. Clin Vaccine Immunol. 2012;19(11):1751-7.
Crisinel, P. A., Posfay-Barbe, K. M., Aebi, C., Cheseaux, J. J., Kahlert, C., Rudin, C., Nadal, D., & Siegrist, C. A. (2012). Determinants of hepatitis A vaccine immunity in a cohort of human immunodeficiency virus-infected children living in Switzerland. Clinical and Vaccine Immunology : CVI, 19(11), 1751-7. https://doi.org/10.1128/CVI.00264-12
Crisinel PA, et al. Determinants of Hepatitis a Vaccine Immunity in a Cohort of Human Immunodeficiency Virus-infected Children Living in Switzerland. Clin Vaccine Immunol. 2012;19(11):1751-7. PubMed PMID: 22933400.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Determinants of hepatitis A vaccine immunity in a cohort of human immunodeficiency virus-infected children living in Switzerland. AU - Crisinel,Pierre Alex, AU - Posfay-Barbe,Klara Maria, AU - Aebi,Christoph, AU - Cheseaux,Jean-Jacques, AU - Kahlert,Christian, AU - Rudin,Christoph, AU - Nadal,David, AU - Siegrist,Claire-Anne, AU - ,, Y1 - 2012/08/29/ PY - 2012/8/31/entrez PY - 2012/8/31/pubmed PY - 2013/4/4/medline SP - 1751 EP - 7 JF - Clinical and vaccine immunology : CVI JO - Clin Vaccine Immunol VL - 19 IS - 11 N2 - Vaccination in HIV-infected children is often less effective than in healthy children. The goal of this study was to assess vaccine responses to hepatitis A virus (HAV) in HIV-infected children. Children of the Swiss Mother and Child HIV Cohort Study (MoCHiV) were enrolled prospectively. Recommendations for initial, catch-up, and additional HAV immunizations were based upon baseline antibody concentrations and vaccine history. HAV IgG was assessed by enzyme-linked immunosorbent assay (ELISA) with a protective cutoff value defined as ≥10 mIU/ml. Eighty-seven patients were included (median age, 11 years; range, 3.4 to 21.2 years). Forty-two patients were seropositive (48.3%) for HAV. Among 45 (51.7%) seronegative patients, 36 had not received any HAV vaccine dose and were considered naïve. Vaccine responses were assessed after the first dose in 29/35 naïve patients and after the second dose in 33/39 children (25 initially naïve patients, 4 seronegative patients, and 4 seropositive patients that had already received 1 dose of vaccine). Seroconversion was 86% after 1 dose and 97% after 2 doses, with a geometric mean concentration of 962 mIU/ml after the second dose. A baseline CD4(+) T cell count below 750 cells/μl significantly reduced the post-2nd-dose response (P = 0.005). Despite a high rate of seroconversion, patients with CD4(+) T cell counts of <750/μl had lower anti-HAV antibody concentrations. This may translate into a shorter protection time. Hence, monitoring humoral immunity may be necessary to provide supplementary doses as needed. SN - 1556-679X UR - https://www.unboundmedicine.com/medline/citation/22933400/Determinants_of_hepatitis_A_vaccine_immunity_in_a_cohort_of_human_immunodeficiency_virus_infected_children_living_in_Switzerland_ L2 - https://journals.asm.org/doi/10.1128/CVI.00264-12?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -